C
ACADIA Pharmaceuticals Inc. ACAD
$16.32 -$0.29-1.75%
Recommendation
Hold
Prev Close
$17.07
Volume
2,613,006
Avg Vol (90D)
2,207,122
Market Cap
$2.85B
Dividend & Yield
--
52-Week Range
$14.15 - $20.68
P/E (TTM)
12.58
EPS (TTM)
$1.36
My Lists My Alerts
Rating
Reward
C
Fair
Risk
D+
Weak
Rating Factors
Growth Index
Good
Efficiency Index
Fair
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Notable Two Hundred Day Moving Average Cross - ACAD
3/31/2025 - Market News Video
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark C. Schneyer Sells 3,171 Shares
3/29/2025 - Ticker Report
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
3/28/2025 - Zacks Investment Research
ACADIA Pharmaceuticals (ACAD, $17.19) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 27, 2025
3/28/2025 - Tickeron - Technical Analysis
James Kihara Sells 1,095 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock
3/28/2025 - MarketBeat
Insider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Sells 3,171 Shares of Stock
3/28/2025 - MarketBeat
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
3/27/2025 - Zacks Investment Research
James Kihara Sells 1,095 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock
3/27/2025 - MarketBeat
EntryPoint Capital LLC Has $478,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
3/27/2025 - MarketBeat
ACADIA Pharmaceuticals (ACAD, $17.03) entered Uptrend as Momentum indicator ascends above 0 level on Mar 26, 2025
3/27/2025 - Tickeron - Technical Analysis
Proficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
3/27/2025 - MarketBeat
Fox Run Management L.L.C. Purchases Shares of 25,422 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
3/26/2025 - Ticker Report
Fox Run Management L.L.C. Purchases Shares of 25,422 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
3/26/2025 - MarketBeat
Cannon Global Investment Management LLC Makes New $2.17 Million Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
3/25/2025 - MarketBeat
Advantage Alpha Capital Partners LP Sells 14,715 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
3/25/2025 - MarketBeat
ACADIA Pharmaceuticals (ACAD, $17.23) entered Uptrend as Momentum indicator ascends above 0 level on Mar 24, 2025
3/25/2025 - Tickeron - Stocks
Brokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $24.00
3/25/2025 - Ticker Report
12 Most Promising Biotech Stocks According to Wall Street Analysts
3/24/2025 - Insider Monkey
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Purchased by Intech Investment Management LLC
3/23/2025 - Ticker Report
What is Zacks Research's Estimate for ACAD Q1 Earnings?
3/21/2025 - MarketBeat
4 Best Stocks To Buy Under $5
3/20/2025 - 24/7 Wall St.
ACADIA Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ACAD)
3/19/2025 - Ticker Report
ACADIA Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ACAD)
3/18/2025 - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Brokerages
3/18/2025 - MarketBeat
How The Pieces Add Up: FBT Targets $219
3/17/2025 - ETF Channel
Income Statement
Total Revenue (TTM)
$957.80M
EBITDA (TTM)
$115.06M
EBIT (TTM)
$99.18M
Net Income (TTM)
$226.45M
Balance Sheet
Total Assets (Q)
$1.19B
Total Debt (Q)
$52.00M
Total Liabilities (Q)
$454.96M
Book Value Per Share (Q)
$4.40
Cash Flow
Cash from Operations (TTM)
$157.72M
Cash from Investing (TTM)
-$30.54M
Cash from Financing (TTM)
$6.85M
Net Change in Cash (TTM)
$133.93M
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.44
7-Day Total Return
-5.01%
30-Day Total Return
-18.56%
60-Day Total Return
-11.06%
90-Day Total Return
-2.68%
Year to Date Total Return
-12.54%
1-Year Total Return
-10.62%
2-Year Total Return
-14.01%
3-Year Total Return
-35.55%
5-Year Total Return
-60.50%
52-week Low
Oct 23, 2024 - $14.15
52-week High
Feb 21, 2025 - $20.68
Valuation
Market Cap
$2.85B - Mid Cap
Enterprise Value
$2.14B
Price/Sales (TTM)
2.97
Price/Book (Q)
3.88
Dividends and Shares
Shares Outstanding
166.70M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.acadia.com
Phone Number
858 558 2871
Address
12830 El Camino Real
San Diego, CA 92130
Country
United States
Year Founded
1993
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United... more
NASDAQ 04/01/2025 4:00PM Eastern Quotes delayed
Weiss Ratings